I'm sure there are. Have at it.
If you find that at one point, they hoped to put IHL-216a through Phase 1 in the next 2 years, congratulations: welcome to biotech startup land. Timelines slip - it is to be expected. Furthermore, they probably STILL hope to initiate a Phase 1 trial for that asset in the next 2 years. They simply can't do it right this minute.
I'm not sure you should be investing in biotech startups if any of this is surprising to you.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-17568
-
- There are more pages in this discussion • 2,422 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)